Contact
Please use this form to send email to PR contact of this press release:
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
TO:
Please use this form to send email to PR contact of this press release:
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
TO: